Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > February 20, 2010 - Volume 24 - Issue 4 > Is HIV-associated tuberculosis a risk factor for the develop...
AIDS:
doi: 10.1097/QAD.0b013e32833547f7
Research Letters

Is HIV-associated tuberculosis a risk factor for the development of cryptococcal disease?

Jarvis, Joseph Na,b,c,d; Harrison, Thomas Sa,b; Corbett, Elizabeth Le,f; Wood, Robina; Lawn, Stephen Da,e

Free Access
Article Outline
Collapse Box

Author Information

aDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

bDepartment of Cellular and Molecular Medicine, Centre for Infection, St George's University of London, London, UK

cInfectious Diseases Research Unit, GF Jooste Hospital, South Africa

dDivision of Infectious Diseases, Department of Medicine, University of Cape Town, Cape Town, South Africa

eDepartment of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK

fMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.

Received 9 October, 2009

Revised 9 November, 2009

Accepted 11 November, 2009

Correspondence to Joseph N. Jarvis, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Faculty of Health Sciences, Anzio Road, Observatory 7925, Cape Town, South Africa. Tel: +27 21 650 6987; fax: +27 21 650 6963; e-mail: joejarvis@doctors.net.uk

Collapse Box

Abstract

Cryptococcal meningitis and tuberculosis are leading causes of mortality in patients initiating antiretroviral therapy in Africa. We hypothesized that a history of tuberculosis may predispose to the development of cryptococcal meningitis and examined the association using multivariate logistic regression in a cohort of patients initiating antiretroviral therapy. History of pulmonary tuberculosis was independently associated with the development of cryptococcal meningitis (odds ratio = 6.6; 95% confidence interval = 1.3–32.7) after adjustment for covariates, including CD4 cell counts. A number of potential mechanisms may underlie this association.

Back to Top | Article Outline

Introduction

Cryptococcal meningitis is a leading cause of mortality in AIDS patients in the developing world [1]. However, the pathophysiology and natural history of infection with Cryptococcus neoformans remain poorly understood. Acute infections following heavy exposure are reported [2], but most HIV-related clinical disease is thought to result from reactivation of ‘latent’ pulmonary infection acquired many years earlier [3]. The key predisposition to disease development is HIV-related loss of T-cell immunity [4]. However, other factors influencing either the acquisition of infection, reactivation or subsequent dissemination are unknown.

In Cape Town, South Africa, we have noted that a substantial proportion of patients with cryptococcal meningitis have a history of tuberculosis (TB). Together, these are two leading causes of morbidity and mortality among patients accessing antiretroviral therapy (ART) in Africa [5] and a possible association between these diseases has previously been noted [6–8]. Although this might simply reflect a shared association with CD4 lymphocytopenia, we hypothesized that TB may directly affect risk of cryptococcal disease via a number of potential mechanisms. We therefore examined this relationship in a cohort of patients enrolling in an ART service in Cape Town [9–11].

Clinical data were collected from consenting patients with approval from the Research Ethics Committee of the University of Cape Town. Data from previous studies of TB [10] and cryptococcal disease [9] were available for sequential patients enrolling in this well characterized ART cohort between September 2002 and April 2005. The main outcome was the development of microbiologically confirmed cryptococcal meningitis during the first year of follow-up and the temporal association with a history of previous TB or prevalent TB (the latter defined as TB episodes that were either diagnosed or already being treated at enrollment). TB diagnoses were established as previously described in detail for this cohort [10]. Statistical comparisons were made using the χ2 or Fisher's exact tests. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression modeling.

Data were available for 707 patients, of whom 26% were men. The median age was 33 years [interquartile range (IQR) = 28–38]; 52% had stage 3 disease and 28% stage 4 disease. The median baseline CD4 cell count was 97 cells/μl (IQR = 46–157) and viral load 76 803 copies/ml (IQR = 33 167–191 030). Most patients (n = 636; 90%) started ART and, of these, 28 (4%) were lost to follow-up and 58 (9%) died during the first year of ART. Among these losses, very few patients (n = 4) had detectable cryptococcal antigen in serum at baseline and all remained free of cryptococcal disease prior to leaving the program (after a median of 47 days). All those lost to follow-up or who died were therefore assumed not to have cryptococcal meningitis at the end of the first year of the study and all 707 patients were included in the analysis.

A history of pulmonary TB (PTB) was recorded in 45% (n = 308) of the cohort and extrapulmonary TB (EPTB) in 8% (n = 55). These episodes (PTB and EPTB) occurred within 2 years prior to enrollment in 66% (n = 241), between 3 and 5 years in 26% (n = 95) and more than 5 years earlier in 7% (n = 27). Prevalent TB was present in 19% (n = 137). Cryptococcal meningitis developed in 2% (n = 13) of the cohort, a median of 35 days after initiating ART; six of these had a history of previous cryptococcal meningitis, a median of 140 days prior to enrollment.

Of patients who developed cryptococcal meningitis, 85% (n = 11) had a history of TB (all PTB). This preceded the initial episode of cryptococcal meningitis in five of the six relapse cases, and only one patient was on rifampicin at the time of relapse. In univariate analysis, a history of previous TB was associated with the development of cryptococcal meningitis (OR = 4.94; 95% CI = 1.1–22.4, P = 0.039). When restricted to PTB, the association was stronger (OR = 6.87; 95% CI = 1.5–31.2, P = 0.013) and when restricted to PTB within 2 years prior to enrollment, the OR was 8.7 (95% CI = 2.4–32.0, P = 0.001). Prevalent TB was not significantly associated with cryptococcal meningitis (OR = 0.75; 95% CI = 0.16–3.4, P = 0.7). Multivariate analysis revealed that both baseline CD4 cell count and history of PTB within the preceding 2 years were strong and independent predictors of the development of cryptococcal meningitis (PTB within 2 years OR = 6.6, 95% CI = 1.3–32.7, P = 0.02; Table 1).

Table 1
Table 1
Image Tools

Despite the common association between CD4 lymphocytopenia and the development of TB and cryptococcal meningitis, our data suggest that a history of PTB within the past 2 years may be an independent risk factor for the subsequent development of cryptococcal meningitis. The observation that prevalent TB episodes were not significantly associated may relate to the fact that any impact on cryptococcal disease risk during the period of follow-up is likely to have been curtailed by the rapid ART-induced restoration of immune function and the resulting protection against cryptococcal meningitis.

A number of possible mechanisms may underlie the observed association between these two diseases. Cryptococcus neoformans is ubiquitous and exposure through inhalation of fungal spores is common [12,13] and yet only approximately 10% of AIDS patients develop cryptococcal disease [4]. This suggests CD4-independent factors may also be important. A shared immunological deficit may allow entry and/or dissemination of both Mycobacterium tuberculosis and Cryptococcus neoformans. Defects in pulmonary innate immune function, for example, may underlie high rates of both TB and cryptococcal disease in gold miners with silicosis [14]. Vitamin D deficiency is associated with defects in the production of cathelicidins by macrophages; these are known to be involved in innate responses to both organisms [15,16]. Posttuberculous lung disease is a strong risk factor for respiratory infections, including low-grade pathogens [17], and might serve as either a portal of entry for new infection, impair clearance, promote reactivation of latent infection or facilitate its dissemination. Convincing evidence exists for latent cryptococcal infection in animal models [18] and humans [19] and reactivation of infections after at least 9 years [3]. Although factors leading to reactivation remain largely unknown, the development of an immunosuppressive phenotype that accompanies active TB [20] could conceivably promote cryptococcal reactivation. Studies are required to explore these various hypotheses.

Patients enrolling in ART cohorts are subject to survival biases and observed associations may be subject to residual confounding. The specificity of the observed association has not been demonstrated and it is possible that the risk of serious opportunistic diseases other than cryptococcal meningitis may also be increased following episodes of TB. Thus, the observed association requires confirmation in prospective studies. The association was nevertheless robust and the temporal relationship plausible. This finding is supported by data showing that cryptococcal disease is an important cause of late mortality in African patients receiving TB treatment [21]. Not only must clinicians be vigilant to the possibility of cryptococcal disease in patients with a recent history of TB, it also may be appropriate to screen such patients for subclinical disease using cryptococcal antigen tests prior to ART initiation.

Back to Top | Article Outline

Acknowledgements

J.N.J., E.L.C. and S.D.L. are supported by the Wellcome Trust, London, UK (WT081794 and 074641). R.W. is funded in part by the National Institutes of Health, USA, through a CIPRA grant 1U19AI53217-01 and RO1 grant (A1058736-01A1).

The authors have no conflicts of interest

Back to Top | Article Outline

References

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525–530.

2. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. N Engl J Med 1993; 328:1354–1355.

3. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37:3204–3209.

4. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119–2129.

5. Lawn S, Harries A, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897–1908.

6. Moosa MY, Coovadia YM. Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clin Infect Dis 1997; 24:131–134.

7. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998; 26:284–289.

8. Corbett EL, Churchyard GJ, Charalambos S, Samb B, Moloi V, Clayton TC, et al. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251–1258.

9. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856–862.

10. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605–1612.

11. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141–2148.

12. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect Immun 2009; 77:3491–3500.

13. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107:E66.

14. Corbett EL, Churchyard GJ, Clayton TC, Williams BG, Mulder D, Hayes RJ, De Cock KM. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14:2759–2768.

15. Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, et al. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 2006; 58:950–959.

16. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179:2060–2063.

17. Corbett EL, Blumberg L, Churchyard GJ, Moloi N, Mallory K, Clayton T, et al. Nontuberculous mycobacteria: defining disease in a prospective cohort of South African miners. Am J Respir Crit Care Med 1999; 160:15–21.

18. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 2000; 68:832–838.

19. Salyer WR, Salyer DC, Baker RD. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis 1974; 130:74–77.

20. Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis 1997; 78:145–158.

21. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733–740.

© 2010 Lippincott Williams & Wilkins, Inc.

Login